Literature DB >> 10895070

Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma.

Y Ito1, T Takeda, M Sakon, M Monden, M Tsujimoto, N Matsuura.   

Abstract

The expression of cyclin-dependent kinase 1 (cdc2), cyclin A and cyclin B1 was immunohistochemically studied in 101 hepatocellular carcinomas (HCC). cdc2 overexpression was directly related to advanced stage, portal invasion, intrahepatic metastasis, poor differentiation, high alpha-fetoprotein level, large size, high Ki-67 labeling index and poor prognosis. Cyclin A and B1 overexpression showed similar tendency to that of cdc2, but they were not recognized as independent prognostic factors by multivariate analysis. These findings suggest that cdc2 plays the most crucial role of the G2/M modulators in cell cycle progression and cell proliferation of HCC and significantly predicts the recurrence of this carcinoma. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10895070     DOI: 10.1159/000012140

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  29 in total

Review 1.  Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis.

Authors:  Yihuan Luo; Fanghui Ren; Yongru Liu; Zhenhong Shi; Zhong Tan; Huojie Xiong; Yiwu Dang; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Protein signature for non-small cell lung cancer prognosis.

Authors:  Wei Liu; Yong Wu; Libo Wang; Ling Gao; Yingping Wang; Xiaoliang Liu; Kai Zhang; Jena Song; Hongxia Wang; Thomas A Bayer; Laurel Glaser; Yezhou Sun; Weijia Zhang; Michael Cutaia; David Y Zhang; Fei Ye
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

3.  Over-expression of p53, p21 and Cdc2 in histologically negative surgical margins is correlated with local recurrence of laryngeal squamous cell carcinoma.

Authors:  Jun-Quan Yang; Hong-Xia Liu; Zhen Liang; Yu-Man Sun; Meng Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Overexpressions of Cyclin B1, cdc2, p16 and p53 in human breast cancer: the clinicopathologic correlations and prognostic implications.

Authors:  Seoung Wan Chae; Jin Hee Sohn; Dong-Hoon Kim; Yoon Jung Choi; Yong Lai Park; Kyungeun Kim; Young Hye Cho; Jung-Soo Pyo; Jun Ho Kim
Journal:  Yonsei Med J       Date:  2011-05       Impact factor: 2.759

5.  Per2 inhibits k562 leukemia cell growth in vitro and in vivo through cell cycle arrest and apoptosis induction.

Authors:  Cheng-ming Sun; Shi-feng Huang; Jian-ming Zeng; Din-bing Liu; Qing Xiao; Wen-jun Tian; Xi-dan Zhu; Zong-gan Huang; Wen-li Feng
Journal:  Pathol Oncol Res       Date:  2009-12-03       Impact factor: 3.201

6.  p34cdc2 expression is an independent indicator for lymph node metastasis in colorectal carcinoma.

Authors:  T Nozoe; M Honda; S Inutsuka; D Korenaga
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-18       Impact factor: 4.553

7.  Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection.

Authors:  Jun Cui; Bao-Wei Dong; Ping Liang; Xiao-Ling Yu; De-Jiang Yu
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

Review 8.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

9.  Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer.

Authors:  Dong-Hoon Kim
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

10.  Knocking-down cyclin A(2) by siRNA suppresses apoptosis and switches differentiation pathways in K562 cells upon administration with doxorubicin.

Authors:  Xiaohui Wang; Yujun Song; Jinsong Ren; Xiaogang Qu
Journal:  PLoS One       Date:  2009-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.